Emergent BioSolutions provides specialty products for civilian and military populations that address intentional and naturally emerging public health threats.

May 15, 2023 · Emergent is built on the foundation of an inclusive, values-driven culture; one with high employee engagement and where a diversity of experiences, backgrounds, and skills drive innovation and operational excellence.

At Emergent, we develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics worldwide. For 25 years, we’ve been at work defending people from things we hope will never happen—so that we’re prepared, just in case they ever do.

As such, Emergent has discontinued production of Trobigard, and the product is no longer available; however, we remain committed to public health preparedness and will continue to work with allied governments to protect soldiers and civilians across the globe.

Emergent BioSolutions is committed to compliance with the DSCSA to help prevent counterfeiting of pharmaceutical products in the industry. Should you have any inquiries regarding our serialized products, you may reach us at one of the following addresses:

Emergent is a hybrid company, with three work options for employees based on the nature of your work: fully-remote, hybrid, or in-office. As a remote employee, you can work grow your career and make an impact from wherever you do it best. Teams with Remote opportunities. Business Support Services; Clinical, Medical & Regulatory; Engineering ...

Emergent has expertise with FDA-approved human and equine plasma products generated for targeted therapy of specific indications. Our hyperimmune specialty plasma product manufacturing platform has been used to create multiple products that have obtained FDA approval, up to a scale of 1000L.

Emergent has secured an agreement with Sandoz to distribute an authorized generic of NARCAN® (naloxone HCl) Nasal Spray 4mg, which will be available to people in the U.S. via retail pharmacies and institutions, including hospitals.

Emergent will consider funding educational grants that support independent, accredited and non-accredited medical education for health care professionals (HCPs). Regardless of whether a program is accredited or non-accredited, Emergent expects the same high standards to apply for all IME activities for HCPs and patients. Funding Priorities

GAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO ® (naloxone HCl) Nasal Spray, an 8 mg naloxone agent that is approved for the emergency treatment of ...